Biosion, Inc.

OBI Pharma Initiates Phase 1/2 Trial for Novel TROP2-Targeted ADC OBI-902 in Advanced Solid Tumors

- OBI Pharma has launched a Phase 1/2 clinical trial for OBI-902, the first antibody-drug conjugate utilizing their proprietary GlycOBI® ADC enabling technology platform. - The study will evaluate OBI-902's safety, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors expressing TROP2 antigen. - OBI-902 demonstrated superior antitumor activities and favorable pharmacokinetics compared to other TROP2 ADCs in preclinical studies presented at AACR 2025. - The FDA cleared the investigational new drug application for OBI-902 in April 2025, with MD Anderson Cancer Center leading the clinical investigation.